Skip to main
MRNA
MRNA logo

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 8%
Hold 46%
Sell 31%
Strong Sell 0%

Bulls say

Moderna's strong outlook is supported by promising clinical data, particularly in its oncology pipeline, demonstrating significant efficacy with satisfactory safety profiles, including no severe adverse effects reported. The company aims to achieve substantial cost reductions of $1.4 to $1.7 billion by 2027 and has reiterated its goal to break even by 2028, enhancing its financial stability. Additionally, Moderna's commitment to advancing mRNA technology across diverse therapeutic areas positions it well for long-term revenue growth and increased market share within the biotech industry.

Bears say

The negative outlook on Moderna's stock is primarily driven by concerns regarding diminishing revenue growth potential from COVID vaccine sales due to waning vaccination rates. Additionally, the firm faces significant competitive challenges with its respiratory vaccine candidates, particularly against established competitors such as Arexvy and Abrysvo, which could limit commercial opportunities. Finally, the overall pipeline progress outside of respiratory vaccines is progressing slowly, further exacerbating revenue uncertainty in both short and medium-term projections.

Moderna (MRNA) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 8% recommend Buy, 46% suggest Holding, 31% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 13 analysts, Moderna (MRNA) has a Hold consensus rating as of Oct 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.